Suchergebnisse - "Best, Jennie H"

PubPharm (17)

11

Development and validation of the self-management profile for type 2 diabetes (SMP-T2D)

enthalten in: Health and quality of life outcomes | 2012

von Peyrot, M. | Bushnell, D. | Best, J. | +3

12

Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens

enthalten in: The American journal of managed care | 2012

von Best, J. | Romley, J. | Goldman, D. | +2

13

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States : results from a retrospective claims database analysis

enthalten in: Journal of medical economics | 2012

von Pelletier, E. | Pawaskar, M. | Smith, P. | +2

14

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

enthalten in: Journal of medical economics | 2012

von Guillermin, A. | Lloyd, A. | Best, J. | +3

15

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

enthalten in: Journal of medical economics | 2012

von Samyshkin, Y. | Guillermin, A. | Best, J. | +2

16

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment

enthalten in: Diabetes care | 2011

von Best, J. | Rubin, R. | Peyrot, M. | +4

17

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies : a retrospective analysis of the LifeLink database

enthalten in: Diabetes care | 2011

von Best, J. | Hoogwerf, B. | Herman, W. | +4